Liofilización de liposomas para su administración pulmonar

  1. Calderón García, Blanca 1
  2. De Jesús Valle, María José 1
  1. 1 Universidad de Salamanca
    info

    Universidad de Salamanca

    Salamanca, España

    ROR https://ror.org/02f40zc51

Journal:
Farmajournal

ISSN: 2445-1355

Year of publication: 2022

Volume: 7

Issue: 2

Pages: 7-17

Type: Article

DOI: 10.14201/FJ202272717 DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Farmajournal

Abstract

Sildenafil citrate has become, in recent years, an oral therapeutic agent used for the treatment of arterial hypertension. Because it has certain limitations, such as a significant reduction in oral bioavailability and pharmacological activity due to first-pass hepatic metabolism, innovative formulations have been proposed for pulmonary administration. This allows minimising systemic adverse effects and the first-pass effect. The aim of the work is to elaborate sildenafil-loaded liposomes and subsequently lyophilise them. Furthermore, to evaluate the flow properties of the solid product obtained for possible pulmonary administration. The liposomes obtained were prepared using the sonication-filtration method, in the absence of organic solvents, and are therefore considered to be biocompatible and biodegradable systems, highly suitable for possible pulmonary administration. They showed high sildenafil encapsulation efficiency (EE% = 85). Adequate solid product flow results were observed with each of the lyoprotectants used, obtaining angle of repose values below 30º and Carr’s index (CI) also below 36 %. Therefore, lyophilisation of liposomes plays a fundamental role in the preservation and stability of these vesicles.

Bibliographic References

  • Barnett CF, Machado RF. Sildenafil in the treatment of pulmonary hypertension. Vascular Health and Risk Management. 2006; 2(4):411-422.
  • Beltrán-Gámez M et al. Inhibidores de fosfodiesterasa-5 para el tratamiento de la hipertensión arterial pulmonar. Archivos Cardiología México. 2015; 85(3):215-224.
  • Blanco O et al. Viscosidad y Tamaño de Partícula de Una Preparación Clínica de Surfactante Pulmonar. Lat. Am. J. Pharm. 2008; 27(5):826-830.
  • De Jesús Valle MJ et al. Lyoprotective Effects of Mannitol and Lactose Compared to Sucrose and Trehalose: Sildenafil Citrate Liposomes as a Case Study. Pharmaceutics 2021; 13(8):1164.
  • De Jesús Valle MJ et al. Sildenafil Citrate Liposomes for Pulmonary Delivery by Ultrasonic Nebulization. Applied Sciences 2018; 8(8):1291.
  • Gaspar MM et al. Inhaled Liposomes-Current Strategies and Future Challenges. J Biomed Nanotechnol. 2008; 4(3):245-257.
  • Gavira Heredia FJ. Preparación de liposomas biocompatibles. Ventaja de su utilización en tratamientos contra el cáncer [Trabajo Fin de Grado]. Sevilla. Universidad de Sevilla; 2020.
  • Haque S et al. Disposition and safety of inhaled biodegradable nanomedicines: Opportunities and challenges. Nanomedicine Nanotechnology, Biol. Med. 2016; 12:1703-1724.
  • Lanio ME et al. Las vesículas liposomales: obtención, propiedades y aplicaciones potenciales en la biomedicina. Rev. Cubana. Fis. 2009; 26(1):23-30.
  • Martínez Pacheco R. Reología de sólidos pulverulentos. En: Martínez Pacheco R, editor. Tratado de Tecnologi?a Farmace?utica. Vol. I. Sistemas farmacéuticos. Madrid: Síntesis; 2016. p. 93-111.
  • Navarro G. Diseño de liposomas para el transporte de diclofenaco sódico Rev. Colomb. Cienc. Quim. Farm. 2008; 37(2):212-223.
  • Rosas RMJR et al. Sildenafil e inhibidores de fosfodiesterasa en hipertensión pulmonar. Neumol Cir Torax. 2006; 65(4):186-200.
  • Saharan VA. Chapter 2: Freeze drying technologies for developing fast dissolving/disintegrating tablets. En: Saharan VA, editor. Current Advances in Drug Delivery Through Fast Dissolving/Dissintegrating Dosage Forms. Sharjah, UAE: Bentham Science Publishers; 2017. p. 35-56.
  • Suñé Negre JM. Nuevas aportaciones galénicas a las formas de administración. Formación continuada para farmacéuticos del hospital. Disponible en: http://www.ub.edu/legmh/capitols/sunyenegre.pdf
  • Zakharova AA et al. Phosphodiesterase type 5 inhibitors greatly affect physicochemical properties of model lipid membranes. Membranes (Basel). 2021; 11(11):893.
Data source: Dialnet